Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced on November 20, 2025 the appointment of Christopher Martin to its Board of Directors.

Mr. Martin brings commercial leadership across marketing, sales, market access, trade and business development and has led multiple product launches. The company said his experience will support preparations for its first commercial launch in Becker muscular dystrophy and efforts to advance its cardiovascular asset to Phase 3. Mr. Martin previously served as Chief Commercial Officer at Verona Pharma, acquired by Merck for approximately $10 billion in October 2025, and held senior commercial roles at SK Life Science, Cempra, Salix Pharmaceuticals and others. He holds a B.S. in Financial Management from Clemson University.

Positive

• Board hire adds experienced commercial leader
• Supports Becker muscular dystrophy first commercial launch prep
• Experience with product launches including Ohtuvayre and XCOPRI
• Verona acquisition by Merck for approximately $10 billion (Oct 2025) indicates prior commercial success

Negative

• None.

News Market Reaction

-0.40%

1 alert

-0.40% News Effect

On the day this news was published, EWTX declined 0.40%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.

"We are thrilled to welcome Chris to our Board of Directors," said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadership will be critical as we prepare for our first commercial launch in Becker muscular dystrophy and advance our cardiovascular asset to Phase 3.

Prior to joining the Edgewise Board, Mr. Martin served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October of 2025. As CCO, Mr. Martin was responsible for building the commercial organization and launch strategy for the company's first product launch, Ohtuvayre® (ensifentrine). Prior, he served as Executive Director of Marketing at SK Life Science which is focused on developing novel therapeutics for central nervous system conditions. Mr. Martin was instrumental in developing the commercial and marketing strategy and the framework for launching their first commercial product, XCOPRI® (cenobamate tablets). Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra where he led the development and launch strategy for the company's first product, solithromycin. Prior to Cempra, he was at Salix Pharmaceuticals for 10 years in roles of increasing responsibility and led the Xifaxan® marketing team during the company's acquisition by Valeant Pharmaceuticals. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

Cautionary Note Regarding Forward-Looking Statements

 This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise's product candidates and programs, including sevasemten, EDG-7500 and EDG-15400; statements regarding Edgewise's ability to commercialize sevasemten; statements regarding Edgewise's ability to advance its cardiovascular asset to Phase 3; and statements by Edgewise's President and Chief Executive Officer. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise's limited operating history, its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having generated any revenue to date; Edgewise's ability to achieve objectives relating to the discovery, development and commercialization of its product candidates, if approved; Edgewise's need for substantial additional capital to finance its operations; Edgewise's substantial dependence on the success of sevasemten and EDG-7500; Edgewise's ability to develop and commercialize sevasemten, EDG-7500 and EDG-15400; risks related to Edgewise's clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise's product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise's clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks relating to interim, topline and preliminary data from Edgewise's clinical trials changing as more patient data becomes available; risks related to failure to develop a proprietary drug discovery platform; risks related to exposure to additional risk if we develop sevasemten and potential other programs in connection with other therapies; risks related to production of drugs by Edgewise's third-party manufacturers; risks related to changes in methods of product candidate manufacturing or formulation; risks related to not achieving adequate market acceptance; risks related to the patient population for our product candidates having a small patient population; risks related to the regulatory approval processes of domestic and foreign authorities being lengthy, time consuming and inherently unpredictable; risks relating to disruptions at the FDA, the SEC and other government agencies; risks relating to Edgewise's ability to attract and retain highly skilled executive officers and employees; Edgewise's ability to obtain and maintain intellectual property protection for its product candidates; Edgewise's reliance on third parties; risks related to future acquisitions or strategic partnerships; risks related to general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that Edgewise files from time to time with the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-302620999.html

SOURCE Edgewise Therapeutics

FAQ

Who is Christopher Martin and why did Edgewise (EWTX) appoint him to the board on November 20, 2025?

Christopher Martin is a commercial biotech executive with launch and commercial operations experience; Edgewise said he will support its first Becker muscular dystrophy launch and Phase 3 cardiovascular development.

How does Christopher Martin's experience at Verona Pharma relate to Edgewise's plans for EWTX?

As Verona Pharma CCO, Mr. Martin built the commercial organization and launch strategy; Edgewise cited this launch leadership as relevant to its upcoming Becker muscular dystrophy launch.

What specific program priorities did Edgewise (EWTX) link to the new board appointment?

Edgewise linked the appointment to preparations for its first commercial launch in Becker muscular dystrophy and advancing its cardiovascular asset to Phase 3.

When was Verona Pharma acquired and for what approximate value mentioned in the Edgewise announcement?

Verona Pharma was acquired by Merck in October 2025 for approximately $10 billion, according to the announcement.

What past product launches has Christopher Martin been involved with before joining Edgewise (EWTX)?

Mr. Martin worked on Ohtuvayre (ensifentrine), XCOPRI (cenobamate), solithromycin development and the Xifaxan marketing team in prior roles.